Talphera Inc., a specialty pharmaceutical company, has announced a significant milestone in its NEPHRO CRRT pivotal trial, with the enrollment of 17 patients in the 70-patient study. This achievement marks approximately 25% of the trial's enrollment and is a critical step towards the completion of the study, which is projected by the end of 2025. The recent acceleration in patient recruitment is attributed to the re-launch of the study with new target profile clinical sites and principal investigators, contributing to over 90% of enrolled patients coming from these new sites. This milestone also fulfills a condition necessary to proceed with the second tranche of a three-tranche financing plan initiated in March 2025. The results of the trial are expected to be presented in the future, as the study progresses towards its planned completion.